Rapid communicationMolecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay☆
References (28)
- et al.
Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow-up
J Urol
(1993) - et al.
Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule
J Urol
(1987) - et al.
Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function
J Urol
(1985) - et al.
The role of vertebral veins in the dissemination of prostatic carcinoma
J Urol
(1981) - et al.
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer
J Urol
(1992) Radical prostatectomy for the treatment of localized prostatic carcinoma
Urol Clin North Am
(1980)- et al.
Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens
J Urol
(1992) - et al.
Computerized tomography and transrectal ultrasound in the assessment of local extension of prostatic carcinoma before radical retropubic prostatectomy
J Urol
(1987) - et al.
Polymerase chain reaction detection of human cytomegalovirus in over 2000 blood specimens correlated with virus isolation and related to urinary virus excretion
J Virol Methods
(1993) - et al.
Correlation of pathologic findings with progression after radical retropubic prostatectomy
Cancer
(1993)
Capsular penetration in prostate cancer: significance for natural history and treatment
Am J Surg Pathol
An assessment of radical prostatectomy. Time trends, geographic variation and outcomes. The Prostate Patient Outcome Research Team
JAMA
Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate
Cancer
Function of vertebral veins and their role in the spread of metastasis
Ann Surg
Cited by (277)
Regional lymph node staging in prostate cancer: Prognostic and therapeutic implications
2009, Surgical OncologyCitation Excerpt :The ProstaScint Scan (Indium In 111 capromab pendetide) showed a very low positive predictive value (11%) and sensitivity (17%) in predicting lymph node involvement [12]. Although initially promising, molecular techniques using reverse transcription polymerase chain reaction (RT-PCR) have demonstrated varying sensitivities in detecting circulating cancer cells and positive PCR assays have been found in men with negative nodes [13]. Thus, the significance of a positive assay remains unknown and for the time being this method cannot determine patients at risk for lymph node metastasis.
Significance of micrometastases in prostate cancer
2008, Surgical OncologyCitation Excerpt :However, not all disseminated cancer cells can adapt to the new microenvironment and proliferate to significant disease, suggesting the need to consider clinically reasonable sensitivity and specificity. In this review, we mainly focused on the detection of micrometastases in pelvic lymph nodes from patients with localized prostate cancer, while intensive studies have also been carried out for identifying disseminated prostate cancer cells to peripheral blood or bone marrow [18,46–52]. In 1994, Katz et al. collected blood samples from 319 patients prior to radical prostatectomy and analyzed these using an RT-PCR targeting PSA.
Recent developments towards portable point-of-care diagnostic devices for pathogen detection
2022, Sensors and DiagnosticsBioimpedance spectroscopy as a potential technique to detect label-free PCR products
2021, Journal of Physics: Conference SeriesCirculating tumor cells as a predictor of treatment response in clinically localized prostate cancer
2019, JCO Precision OncologyStrategies for isolation and molecular profiling of circulating tumor cells
2017, Advances in Experimental Medicine and Biology
- ☆
This study was supported by grants from the New York Academy of Medicine (Ferdinand C. Valentine Scholar) (A.E.K.), from the National Institutes of Health, NCRR, M01 RR00645 (D.M.); from the National Cancer Institute, CA58089 (R.B.); and from the Maimonides Research Foundation (C.C.).